IFN- activates the JAK/STAT pathway, and TNF- activates the MAPK and NF-kB pathways, both contributing to inflammation and cell damage
They are available on NHS prescription when NICE criteria are met (as outlined in NICE NG28 for type 2 diabetes and relevant technology appraisals for weight management), and are administered via subcutaneous injection, typically weekly or daily depending on the formulation
COPYRIGHT: 2025 European Society of Medicine
Mega Doctor News Medical News Today The Food and Drug Administration (FDA) has approved Eli Lillys once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems
Schneider-Helmert, D., & Schoenenberger, G